From Bench to Bedside: Discovery of the First FDA‐ Approved Antibody Therapeutic for Migraine

This seminar is part of the Amgen Biotech Series open to students, trainees, and scholars. We will discuss the path of Aimovig (erenumab), a first‐in‐class antibody therapeutic for prevention of migraine, from early discovery through development to delivery to patients.

When 3:00 pm to 4:00 pm on Tuesday, October 13, 2020
Location Virtual via Zoom